AJMC November 12, 2024
Interview by Mary Caffrey

Key Takeaways

  • The $2000 Medicare Part D out-of-pocket cap is likely to remain, despite its high cost to the federal government.
  • Potential changes to the IRA’s price negotiation features could occur, especially with a Republican-controlled Congress.
  • The Most Favored Nation policy for drug pricing may be revisited, though its future remains uncertain.
  • 340B program reforms and PBM reforms are likely priorities, with bipartisan support for transparency and compensation delinking.
  • RFK Jr. may play a significant advisory role in health policy, potentially influencing drug policy and public health initiatives.

Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of the election.

Last week’s election results...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Health System / Hospital, Interview / Q&A, Pharma, Pharma / Biotech, Provider, Trends
3 Ways The New Administration Could Speed The Path To New Medicines
Dear President-Elect Trump: To Reach The Next Cure, Fix These Policies
What’s a pandemic pact without the US?
What The Election Means For Federal Health Care Legislation
What the Trump election means for Microsoft’s AI dreams

Share This Article